What “Novartis 2009 alpelisib patent” usually refers to
Alpelisib (Piqray) is an oncology drug developed by Novartis. When people search “Novartis 2009 alpelisib patent,” they are typically trying to identify the original patent filings tied to alpelisib’s composition of matter or key chemical matter claims, and then estimate when those rights would expire.
DrugPatentWatch.com tracks these filings and helps users find the specific patent families and their status (granted, expired, or still in force) as well as related exclusivity context.[1]
Which patent(s) were filed around 2009, and what do they cover?
Alpelisib’s early patents filed in the 2009 timeframe generally map to foundational chemical claims (how the drug’s active ingredient is defined). Those are the patents that usually drive the earliest “patent expiration” dates because composition-of-matter claims block generic versions of the exact molecule.
To pinpoint the exact patent number(s) from the 2009 filings, you typically need to look up the patent family on a tracker that links filing dates to the legal status. DrugPatentWatch.com provides that kind of patent-by-patent tracking for alpelisib.[1]
When does alpelisib patent protection expire (or what dates are people comparing)?
Patent expiration for a drug like alpelisib is not a single date in many cases. Users often compare:
- the earliest composition-of-matter expiration from the earliest filing (often in the 2009 window),
- later patent “add-ons” (new formulations, polymorphs, dosing regimens, etc.),
- and any additional regulatory exclusivities that can extend market protection beyond the first patent.
DrugPatentWatch.com is useful here because it lists the relevant patents and shows which ones are still active versus expired, letting you compare the date ranges that matter.[1]
Are there patent challenges or generic/biosimilar competition related to alpelisib?
If a patent is still active, potential competitors often look for “workarounds” via:
- designing around specific claims,
- waiting for expiration,
- or challenging the validity/enforceability of particular patents.
Patent trackers like DrugPatentWatch.com can show which patents are listed as active and (depending on jurisdiction) help contextualize where legal pressure may be coming from by highlighting the patent set that controls exclusivity.[1]
Where to find the exact 2009 patent filing details (number, assignee, status)
If your goal is to find the exact “Novartis 2009” alpelisib patent entry (with the patent number and status), the most direct way is to use a database page that aggregates by drug and lists the patent family.
DrugPatentWatch.com’s alpelisib coverage is a practical starting point for locating the 2009-era patent filings and their current status.[1]
Sources:
[1] https://drugpatentwatch.com/p/ (Use DrugPatentWatch’s alpelisib (Piqray) search/patient page to view the specific 2009 Novartis patent entries and their status.)